Ads
related to: metastatic prostate cancer medications
Search results
Results From The WOW.Com Content Network
Antiandrogens are medications such as flutamide, nilutamide, bicalutamide, enzalutamide, apalutamide, and cyproterone acetate that directly block the actions of testosterone and DHT within prostate cancer cells. In men with metastatic, hormone-sensitive prostate cancer, doctors may recommend adding taxane-based chemotherapy to hormone therapy. [45]
Prostate tumors were first described in the mid-19th century, during surgeries on men with urinary obstructions. Initially, prostatectomy was the primary treatment for prostate cancer. By the mid-20th century, radiation treatments and hormone therapies were developed to improve prostate cancer treatment.
The number of new cases of metastatic, or stage 4, prostate cancer shot up 72 percent between 2004 and 2013, according to the Northwestern Medicine study. Overall, one in nine men in the U.S. will ...
Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. [10] Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).
Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
Ads
related to: metastatic prostate cancer medications